title: Can cardiovascular disease guidelines that advise treatment decisions based on absolute risk be improved?
abstract: Cardiovascular disease (CVD) will remain the predominant cause of death and a major cause of morbidity for the foreseeable future. Consequently, CVD prevention offers the greatest potential for the prevention of premature mortality and the compression of morbidity.
  
  
  
  The 2013 guidelines of the American College of Cardiology and the American Heart Association expand the eligibility for CVD preventive treatment based on the calculated 10-year CVD risk derived from the pooled cohort equation to all persons who have a 10-year risk of CVD of ≥7.5% as estimated by the pooled cohort equation. Previous analyses show that the use of a uniform 10-year risk threshold of 7.5% for all ages disadvantages younger individuals for whom preventive therapy has most to offer. Here I show that reducing the threshold to 3% in younger adults (women aged <66 years and men aged <56 years) will substantially increase the number of cardiovascular events prevented at a similar number needed to treat to prevent one event. Importantly, this increase in cardiovascular event prevention will occur in individuals with greater life expectancy.
  
  
  
  Reducing the threshold 10-year risk of CVD derived from the pooled cohort equation for CVD preventive treatment to 3% in younger adults (women aged <66 years and men aged <56 years) will more effectively prevent premature mortality and compress morbidity to an older age.
authors.affiliation: Department of Molecular Cardiology, St. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia. dcampbell@svi.edu.au.|The University of Melbourne, Parkville, VIC, Australia. dcampbell@svi.edu.au.
authors.forename: Duncan J
authors.initials: DJ
authors.lastname: Campbell
mesh_terms: D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D003657:Decision Making; D014943:Global Health; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D015994:Incidence; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D012308:Risk Management / Q000379:methods*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Absolute risk; Prediction; Statins